Name: Besifloxacin Hydrochloride
Price: 185.00 USD

- Overview
  - Besifloxacin is the Hydrochloride salt form of Besifloxacin a broad-spectrum, fourth-generation, 8-chloro-fluoroquinolone antibiotic agent. Besifloxacin Hydrochloride is the commercially available form developed by SSP Co Ltd, Japan. It is active against both Gram-positive and Gram-negative, aerobic and anaerobic bacteria. It is primarily used against bacteria causing bacterial conjunctivitis. Besifloxacin stops the production of pro-inflammatory cytokines in vitro.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Besifloxacin has a uniquely balanced dual-targeting activity that inhibits both DNA gyrase and topoisomerase IV at nearly equal concentrations. It is associated with a lower incidence of resistance development. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV by binding to the enzyme-DNA complex generating persistent, covalent enzyme–DNA adducts, inhibiting DNA synthesis.
- Properties
  - CAS Number
    
    1398566-43-2
    
    Molecular Formula
    
    C19H21ClFN3O3 · HCl
    
    Molecular Weight
    
    430.30
    
    Appearance
    
    Off-white or light yellow powder
    
    Solubility
    
    Slightly soluble in DMSO (warmed) and methanol. Very slightly soluble in water (warmed).
    
    Other Properties
    
    Source: Synthetic
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Besifloxacin Hydrochloride displays activity against both Gram-positive and Gram-negative bacteria including ocular bacteria Streptococcus pneumonia, Staphylococcus aureus, S. epidermidis, Haemophilus influenza, Moraxella catarrhalis and Corynebacterium spp.
    
    Microbiology Applications: In vitro, Besifloxacin has demonstrated equivalent or superior activity compared with other commonly used topical antibiotics. In vivo, besifloxacin has consistently demonstrated efficacy and safety against bacterial conjunctivitis. Besifloxacin is not marketed in other formulations, ensuring that its exposure is limited to bacterial populations in and around the eye. Basifloxacin is effective against ocular pathogens such as Corynebacterium pseudodiphtheriticum, Moraxella lacunata, Staphylococcus spp. and Streptococcus spp.
    
    Eukaryotic Cell Culture Applications: Besifloxacin acts as an anti-inflammatory agent in monocytes in vitro. Cytokine expression in human THP-1 monocytes was stimulated by lipopolysaccharide (LPS). Cytokine expression in human THP-1 monocytes was stimulated by LPS (Zhang and Ward, 2008).